The difficulty is that the effect of FKN on the functioning of the immune system in the TME is complex and depends on the type of cancer and the heterogeneity of a specific tumor, which affects the expression of FKN and CX3CR1 in cells. The gene discussed is CX3CL1; the disease is neoplasm.